PMV Pharmaceuticals, Inc. (PMVP)
NASDAQ: PMVP · Real-Time Price · USD
1.190
-0.090 (-7.03%)
At close: Dec 5, 2025, 4:00 PM EST
1.220
+0.030 (2.54%)
After-hours: Dec 5, 2025, 7:31 PM EST
PMV Pharmaceuticals Employees
PMV Pharmaceuticals had 47 employees as of December 31, 2024. The number of employees decreased by 16 or -25.40% compared to the previous year.
Employees
47
Change (1Y)
-16
Growth (1Y)
-25.40%
Revenue / Employee
n/a
Profits / Employee
-$1,759,681
Market Cap
63.32M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 47 | -16 | -25.40% |
| Dec 31, 2023 | 63 | 1 | 1.61% |
| Dec 31, 2022 | 62 | 8 | 14.81% |
| Dec 31, 2021 | 54 | 10 | 22.73% |
| Dec 31, 2020 | 44 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PMVP News
- 6 weeks ago - PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation - GlobeNewsWire
- 7 weeks ago - PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 3 months ago - Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types - Benzinga
- 3 months ago - PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation - GlobeNewsWire
- 4 months ago - PMV Pharmaceuticals (PMVP) Q2 Loss Jumps - The Motley Fool
- 4 months ago - PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights - GlobeNewsWire
- 7 months ago - PMV Pharmaceuticals to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 9 months ago - PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights - GlobeNewsWire